All companies
Visit website
BioCurity Pharmaceuticals Inc.
OperatingBIOCURITY PHARMACEUTICALS INC.
Biotech · Founded 2010
Because fighting cancer is hard enough!
Post-money valuation ⓘ
$36.6M
As of May 2021 · from BioCurity Pharmaceuticals Inc. Stock 2 · pre-money + amount raised, not a traded price
Total raised
$455,388
Across 2 rounds since 2019
Latest share price
$4.25
BioCurity Pharmaceuticals Inc. Stock 2 offering price
Financials
FY2017–FY2022 · from SEC filings · hover any figure for its source$0
−$2.8M
2017
$0
−$1.6M
2018
$0
−$2.2M
2019
$0
−$2.2M
2020
$0
−$5.4M
2021
$0
−$2.7M
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
Income statement
Revenue
$0
$0
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
Net income
-$2,844,968
-$1,570,893
-$2,191,060
-$2,164,862
-$5,449,601
-$2,714,265
Taxes paid
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$203,307
$167,281
$62,215
$49,572
$79,363
$60,228
Accounts receivable
$0
$0
$0
$0
$0
$0
Total assets
$409,874
$342,484
$222,611
$209,698
$201,161
$167,746
Short-term debt
$1,320,617
$780,203
$1,524,330
$2,644,002
$3,518,421
$4,498,091
Long-term debt
$0
$0
$0
$0
$0
$0
Total liabilities
$1,320,617
$780,203
$1,524,330
$2,644,002
$3,518,421
$4,498,091
Other
Headcount
—
1
1
0
0
0
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$34.4M
post-money
$36.6M
post-money
Biocurity Stock 1
BioCurity Pharmaceuticals Inc. Stock 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $228.5K / $600KInvestors 198Post-money $36.6M
Raised $226.9K / $1.1MInvestors 177Post-money $34.4M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 4 of 7 annual reports (FY2019–FY2025)
198 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 35 filings on EDGARSource: ManualCIK 0001639681Share price $4.25
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.